Novel GTF2I-PDGFRB and IKZF1-TYW1 fusions in pediatric leukemia with normal karyotype by Panagopoulos, Ioannis et al.
Panagopoulos et al. Exp Hematol Oncol            (2019) 8:12  
https://doi.org/10.1186/s40164-019-0136-y
CASE REPORT
Novel GTF2I–PDGFRB and IKZF1–TYW1 
fusions in pediatric leukemia with normal 
karyotype
Ioannis Panagopoulos1* , Marta Brunetti1, Margrethe Stoltenberg1, Rønnaug A. U. Strandabø1, 
Julie Staurseth1, Kristin Andersen1, Ilyá Kostolomov2, Tarjei S. Hveem2, Susanne Lorenz3, Tove Anita Nystad4, 
Trond Flægstad4,5, Francesca Micci1 and Sverre Heim1,6
Abstract 
Background: Many cases of acute lymphoblastic leukemia (ALL) carry visible acquired chromosomal changes of 
pathogenetic, diagnostic, and prognostic importance. Nevertheless, from one-fourth to half of newly diagnosed ALL 
patients have no visible chromosomal changes detectable by G-banding analysis at diagnosis. The introduction of 
powerful molecular methodologies has shown that many karyotypically normal ALLs carry clinically important submi-
croscopic aberrations.
Case presentation: We used fluorescence in situ hybridization (FISH), array comparative genomic hybridization 
(aCGH), RNA sequencing, reverse transcription (RT) and genomic polymerase chain reaction (PCR), as well as Sanger 
sequencing to investigate a case of pediatric ALL with a normal karyotype. FISH with a commercial PDGFRB breaka-
part probe showed loss of the distal part of the probe suggesting a breakpoint within the PDGFRB locus. aCGH 
revealed submicroscopic deletions in chromosome bands 5q32q35.3 (about 30 Mb long, starting within PDGFRB 
and finishing in the CANX locus), 7q34 (within TCRB), 9p13 (PAX5), 10q26.13 (DMBT1), 14q11.2 (TRAC ), and 14q32.33 
(within the IGH locus). RNA sequencing detected an in-frame GTF2I–PDGFRB and an out-of-frame IKZF1–TYW1 fusion 
transcript. Both fusion transcripts were verified by RT-PCR together with Sanger sequencing and interphase FISH. The 
GTF2I–PDGFRB fusion was also verified by genomic PCR and FISH. The corresponding GTF2I–PDGFRB fusion protein 
would consist of almost the entire GTF2I and that part of PDGFRB which harbors the catalytic domain of the tyrosine 
kinase. It would therefore seem to lead to abnormal tyrosine kinase activity in a manner similar to what has been seen 
for other PDGFRB fusion proteins.
Conclusions: The examined pediatric leukemia is a Ph-like ALL which carries novel GTF2I–PDGFRB and IKZF1–TYW1 
fusion genes together with additional submicroscopic deletions. Because hematologic neoplasms with PDGFRB-
fusion genes can be treated with tyrosine kinase inhibitors, the detection of such novel fusions may be clinically 
important. Since the GTF2I–PDGFRB could be detected only after molecular studies of the leukemic cells, further inves-
tigations of ALL-cases, perhaps especially but not exclusively with a normal karyotype, are needed in order to deter-
mine the frequency of GTF2I–PDGFRB in leukemia, and also to find out which clinical impact the fusion may have.
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Background
Most cases of acute lymphoblastic leukemia (ALL) carry 
visible acquired chromosomal changes of pathogenetic, 
diagnostic, and prognostic importance [1]. However, up 
to 43% of newly diagnosed ALL patients are reported to 
carry normal G-banded karyotypes at diagnosis [2–4]. 
The introduction of powerful molecular methodologies 
such as fluorescence in  situ hybridization (FISH), array 
based gene expression analysis of mRNA and miRNA, 
array comparative genomic hybridization (aCGH), sin-
gle nucleotide polymorphism (SNP) arrays, and, very 
recently, whole genome sequencing, whole-exome 
sequencing, and RNA sequencing, has shown that many 
of the karyotypically normal ALLs nevertheless carry 
clinically important submicroscopic genetic aberrations 
[2, 5–9]. Using SNP methodology, Paulsson et  al. [6] 
showed that almost all 45 examined adult and adolescent 
ALL cases carried cryptic genetic changes. Similar results 
were obtained by Okamoto et  al. [7] who studied with 
SNP methodology 75 adult ALLs and compared them 
with 399 pediatric ALLs, and by Othman et  al. [8] who 
studied 61 karyotypically normal ALL cases. A common 
theme in the published studies is that deletions of genes 
involved in B lymphopoiesis and cell-cycle regulation, 
such as CDKN2A, EBF1, ETV6, IKZF1, PAX5, and RB1, 
occur with a high frequency [6–8].
In the present study, we used FISH, aCGH, and RNA 
sequencing to further examine a karyotypically normal 




The patient was a 3 years old girl who for 2 months had 
symptoms and signs of disease with fever and reduced 
general condition. The last week she had nose bleedings, 
petechiae, and pain from the throat and abdomen. The 
initial blood tests showed hemoglobin 4.3 g/dL (normal 
11–14  g/dL), leukocytes 72 × 109/L (normal 4 × 109/
L–15 × 109/L), and thrombocytes 19 × 109/L (normal 
150 × 109/L–450 × 109/L). The blood and bone marrow 
smears revealed that the patient had acute lymphoblas-
tic leukemia. Immunophenotyping of peripheral blood 
showed 80% pre-B-lymphoblasts, in the bone marrow 
88%. The patient was treated according to the NOPHO 
ALL 2008 protocol, high-risk group [10]. She started 
with induction treatment, but the bone marrow on day 
15 showed 90% lymphoblasts. The treatment was there-
fore changed to block treatment according to the proto-
col, and on day 34 minimal residual disease (MRD) was 
less than 0.01%. Also repeated later measurements have 
shown MRD of less than 0.01%.
Genetic analyses
The G-banding analysis at diagnosis of bone marrow 
and blood metaphase cells revealed a normal karyotype, 
46,XX, in all 25 examined metaphases (Fig.  1a). Inter-
phase FISH analyses with the Cytocell (Cytocell, Ban-
bury, Oxfordshire, UK) multiprobe ALL panel did not 
detect aberrations of MYC, CDKN2A, TCF3, MLL, and 
IGH, no ETV6-RUNX1 or BCR-ABL1 fusions, nor was 
hyperdiploidy seen in 200 examined nuclei (data not 
shown). FISH with the PDGFRB breakapart probe (Cyto-
cell) showed loss of the distal part of the probe in 176 
out of 201 examined interphase nuclei from white blood 
cells and 42 out of 100 examined interphase nuclei from 
bone marrow cells, suggesting a genetic breakpoint in the 
PDGFRB locus in 5q32 (Fig. 1b).
aCGH was performed with genomic DNA extracted 
from the patientʼs peripheral blood cells using the Max-
well 16 Instrument System and the Maxwell 16 Cell DNA 
Purification Kit (Promega, Madison, USA). Promegaʼs 
human genomic female DNA (Promega, Madison, USA) 
was used as reference DNA. For aCGH, the CytoSure 
array products were used (Oxford Gene Technology, Beg-
broke, Oxfordshire, UK) following the company’s proto-
cols. The CytoSure Genomic DNA Labelling Kit was used 
for labelling of one μg of patient’s and reference DNA, the 
CytoSure Cancer +SNP array was used for hybridization, 
and the CytoSure Interpret analysis software was used to 
analyse the results.
aCGH revealed submicroscopic deletions in chro-
mosome bands 5q32q35.3, 7q34 (within TCRB), 9p13 
(PAX5), 10q26.13 (DMBT1), 14q11.2 (TRAC ), and 
14q32.33 (within the IGH locus) (Fig.  1c, Table  1). The 
deletion on 5q was 30  Mb long, started between exons 
8 and 9 of PDGFRB (5q32), and finished in the CANX 
locus (5q35.3). The result was in agreement with the 
FISH data obtained with the PDGFRB breakapart probe 
(Fig. 1b, c). Because both FISH and aCGH findings indi-
cated a possible PDGFRB-fusion gene, one µg of the total 
RNA, extracted from the patient´s bone marrow at the 
time of diagnosis using miRNeasy Mini Kit (Qiagen Nor-
dic, Oslo, Norway), was sent to the Genomics Core Facil-
ity at the Norwegian  Radium Hospital, Oslo University 
Hospital  (http://genom ics.no/oslo/) for high-throughput 
paired-end RNA-sequencing. For library preparation 
from total RNA the Illumina TruSeq RNA Access Library 
Prep kit was used according to Illuminaʼs protocol (Illu-
mina, San Diego, CA, USA; https ://suppo rt.illum ina.
com/conte nt/dam/illum ina-suppo rt/docum ents/docum 
entat ion/chemi stry_docum entat ion/sampl eprep s_truse 
q/truse qrnaa ccess /truse q-rna-acces s-libra ry-prep-guide 
-15049 525-b.pdf). Sequencing was performed on Next-
Seq  550 System (Illumina) and 16 million reads were 
generated.
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Because the raw fastq RNA sequencing data were in 
the text-based format, we used the “grep” command-line 
utility to search for sequences which contained part of 
the ninth exon of PDGFRB [11]. Using the search term 
“TCC CTG TCC GAG TGC TGG ”, which corresponds to 
1713–1730 nt in the PDGFRB reference sequence with 
accession number NM_002609.3, only one 76  bp long 
sequence was extracted (Fig. 2a). BLAT of this sequence 
on the human genome browser-hg19 assembly (http://
genom e-euro.ucsc.edu/cgi-bin/hgGat eway) showed that 
the sequence between nucleotides 26–76 mapped on 
chromosome 5 at position 149510177–149510227 and 
was part of exon 9 of PDGFRB. The sequence between 
nucleotides 1–27 (GCC AGT TGG AAG TTC CAG CCA 
CAG AAG) mapped on chromosome 7 at three differ-
ent positions: (a) chr7:74172307–74172333 (exon 32 
of general transcription factor Iii, GTF2I, reference 
sequence: NM_032999.3), (b) chr7: 74603796–74603822 
(exon 22 of general transcription factor IIi pseudogene 
1, GTF2IP1, reference sequence: NR_002206.3), and 
(c) chr7:72618618–72618644 (exon 22 of general tran-
scription factor IIi pseudogene 4, GTF2IP4, reference 
sequence: NR_003580.2). These data were verified when 
we used the BLAST algorithm (http://blast .ncbi.nlm.nih.
gov/Blast .cgi) to compare the sequence with the refer-
ence sequences NM_002609.3 (PDGFRB), NM_032999.3 
(GTF2I), NR_002206.3 (GTF2IP1), and NR_003580.2 
(GTF2IP4).
In order to confirm the existence of the GTF2I–PDG-
FRB fusion gene, reverse transcription (RT) and genomic 
PCR analyses were performed as previously described 
[12]. The primers used for PCR amplifications and Sanger 
sequencing analyses are shown in Table 2. RT-PCR with 
the primers GTF2I-3306F1/PDGFRB-1732R1 ampli-
fied an 84  bp long cDNA fragment. Sanger sequencing 
of the PCR products verified the fusion which was found 
upon searching the RNA sequencing data using the 
“grep” command (Fig.  2b). Thus, the leukemic cells car-
ried either the fusion transcript GTF2IP1-PDGFRB, or 
GTF2I–PDGFRB, or GTF2IP4-PDGFRB. Genomic PCR 
Fig. 1 G-banding, FISH, and aCGH analyses. a The G-banding analysis showed a normal karyotype, 46,XX. b Interphase FISH with the PDGFRB 
breakapart probe on a normal nucleus and on a nucleus with loss of the distal probe suggesting a genetic breakpoint in the PDGFRB locus. c aCGH 
showing deletions on chromosome bands 5q32q35.3, 7q34, 9p13, 10q26.13, 14q11.2, and 14q32.33
Table 1 The results of aCGH obtained in the pediatric ALL 




Start Stop Size Imbalances
5q32q35.3 149511500 179127000 29.62 Mb Loss
7q34 142004630 142500344 495.7 Kb Loss
9p13.2 36929656 37030664 101.01 Kb Loss
10q26.13 124339069 124380607 41.54 Kb Loss
14q11.2 22691684 22951081 260 Kb Loss
14q32.33 106167466 107240718 1.07 Mb Loss
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Fig. 2 Molecular genetic and FISH analyses for identification of the GTF2I–PDGFRB fusion gene. a The 76 bp sequence obtained from the raw data 
of RNA sequencing using the command “grep”. The search term “TCC CTG TCC GAG TGC TGG ” is underlined. b Partial sequence chromatogram of the 
PCR amplified cDNA fragment showing the fusion (arrow) of GTF2I and PDGFRB. c Partial sequence chromatogram of the PCR amplified genomic 
DNA fragment showing the fusion (arrow) of GTF2I and PDGFRB. The identification of the GTF2I gene as the PDGFRB-fusion partner was possible 
only after FISH experiments using appropriate commercial BAC probes for PDGFRB and GTF2I. d Ideogram of chromosome 5 showing the mapping 
position of the PDGFRB gene (vertical red line). e Diagram showing the FISH probe RP11-21I20 for PDGFRB. Additional genes in this region are also 
shown. f Ideogram of chromosome 7 showing the mapping position of the GTF2I gene (vertical green line). g Diagram showing the FISH probe 
RP11-137E8 for GTF2I. Additional genes in this region are also shown. h FISH on interphase nuclei with the PDGFRB (red signal) and GTF2I (green 
signal) probes showing a red signal, a green signal and one yellow-fusion signal (arrow)
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with the primers GTF2I-3317F1 and PDGFRB-1737R1 
amplified a single 1200  bp fragment which by Sanger 
sequencing was shown to be a hybrid genomic DNA frag-
ment in which intron 8 of PDGFRB is fused with either 
intron 22 of GTF2IP1, intron 32 of GTF2I, or intron 22 
of GTF2IP4 (Fig. 2c). Additional interphase FISH experi-
ments were performed to detect the GTF2I–PDGFRB 
fusion gene (Fig.  2d–h). BACs RP11-21I20 and RP11-
137E8 were retrieved from the Human “32K” BAC Re-
Array library (BACPAC Resources, https ://bacpa creso 
urces .org/home.htm). RP11-21I20, the probe for the 
PDGFRB gene, mapped to band 5q32 (Position: chr5: 
149,320,375–149,496,703; UCSC Genome Browser on 
Human February 2009 GRCh37/hg19 Assembly) and 
was labeled red (Fig.  2d, e). RP11-137E8, the probe for 
the GTF2I gene, mapped to band 7q11.23 (Position: chr7: 
73,944,720–74,129,587) and was labeled green (Fig.  2f, 
g). Detailed information about the FISH procedure was 
given previously [13]. Fluorescent signals were captured 
and analyzed using the CytoVision system (Leica Bio-
systems, Newcastle, UK). FISH analysis showed a fusion 
signal in 44 out of 100 examined interphase nuclei from 
bone marrow cells suggesting a GTF2I–PDGFRB fusion 
gene (Fig. 2h). Thus, FISH with specific probes for PDG-
FRB and GTF2I was crucial to show that a novel GTF2I–
PDGFRB fusion gene had been formed (Fig. 2d–h).
Using the FusionCatcher software [14] with the fastq 
files of the RNA sequencing data, an out-of-frame 
IKZF1–TYW1 fusion transcript was found (Fig. 3a).
RT-PCR with the primers IKZF1-469F1/TYW1-
1282R1 (Table  2) amplified a 319  bp long cDNA frag-
ment which by Sanger sequencing was shown to 
contain IKZF1–TYW1 (Fig.  3b). The fusion point thus 
detected was identical to that found by analysis of the 
RNA sequencing data using the FusionCatcher soft-
ware (Fig.  3a, b). In the IKZF1–TYW1 transcript, exon 
4 of IKZF1 (nt 642 in sequence with accession number 
NM_006060 version 6) was fused out-of-frame to exon 8 
of TYW1 (nt 1131 in NM_018264 version 4) (Fig. 3b).
The IKZF1–TYW1 fusion gene would encode a puta-
tive truncated 159 aa IKZF1 protein containing the first 
140 aa of IKZF1 (NP_006051) and 19 aa from the fused 
TYW1. This protein would not contain the functional 
domains of the normal IKZF1 protein. Alterations of 
IKZF1 (often deletions) are strongly associated with 
BCR-ABL1-positive as well as Ph-like ALL [15, 16].
Additional interphase FISH experiments were per-
formed to detect the IKZF1–TYW1 fusion gene using 
a home-made dual color dual fusion probe. The probes 
were made from commercial BACs which were pur-
chased from BACPAC Resources Center (https ://bacpa 
creso urces .org). The probe for the IKZF1 gene was con-
structed from a pool of the clones RP11-813K3 (Accesion 
number AC020743; Position: chr7: 50157413–50339940) 
and RP11-95E2 (Accesion number AC018705; chr7: 
50475184–50648153) and was labeled red (Fig. 3c, d). The 
probe for the TYW1 gene was constructed from a pool 
of the clones RP11-458F8 (Accesion number AC073335; 
Position: chr7: 66297269–66454983) and RP11-166O4 
(Accesion number AC006480; Position: Chr7: 66699524–
66859231) and was labeled green (Fig. 3c, e).
FISH analysis showed double fusion signals in 91 out 
of 100 examined interphase nuclei from white blood cells 
suggesting an IKZF1–TYW1 fusion gene (Fig. 3f ).
Discussion
We present here a case of pediatric leukemia with a 
normal karyotype, 46,XX, but with multiple hidden 
aberrations identified using a combination of aCGH, 
RNA sequencing, and FISH methodologies. The ini-
tial FISH analysis with a PDGFRB breakapart probe 
showed loss of the distal part of the probe suggest-
ing a genetic rearrangement of the PDGFRB gene. 
Because loss of the distal part of the probe was seen 
in interphase nuclei and not on metaphase spreads, 
we concluded that the normal karyotype was from 
non-leukemic cells whereas the leukemic cells did not 
divide in vitro. Subsequent analyses by aCGH revealed 
submicroscopic deletions within the TCRB (7q34), 
PAX5 (9p13), DMBT1 (10q26.13), 14q11.2 (TRAC ), 
and IGH (14q32) loci, as well as loss of a 30 Mb stretch 
which started with PDGFRB (5q32) and finished in 
the CANX locus (5q35.3). The aCGH results were in 
agreement with previous findings of submicroscopic 
Table 2 Primers used for PCR amplification and Sanger sequencing analyses
Name Sequence (5′– > 3′) Position Reference sequence Gene
GTF2I-3306F1 AAT CAG CTG AAC CAA GCC AGTTG 3306–3328 NM_032999.3 GTF2I
PDGFRB-1732R1 TGT CAG GGT GGC TCT CAC TTAGC 1732–1754 NM_002609.3 PDGFRB
GTF2I-3317F1 CCA AGC CAG TTG GAA GTT CCA GCCA 3317–3341 NM_032999.3 GTF2I
PDGFRB-1737R1 TCC CCA CTG TCA GGG TGG CTC TCA C 1737–1761 NM_002609.3 PDGFRB
IKZF1-469F1 GAA TGC TTG ATG CCT CGG GAGA 469–490 NM_006060.6 IKZF1
TYW1-1282R1 CCG AGT GGC TCC CAA TCA ACTG 1282–1303 NM_018264.3 TYW1
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deletions found at high frequencies in ALL [2, 6–8]. 
Many PAX5 deletions were reported in BCR-ABL1-
positive and Ph-like ALL [6, 7, 17]. DMBT1 deletions 
were reported in tumors of the central nervous sys-
tem but this gene’s role, if any, in ALL development 
remains unknown [18, 19]. Finally, concomitant dele-
tions within the immune loci TCR (alpha/delta and 
gamma) and IGH, which are often accompanied by 
deletions within IKZF1, were shown to be associated 
with lymphoid blast transformation of chronic myeloid 
Fig. 3 Molecular genetic and FISH analyses for identification of the IKZF1–TYW1 fusion gene. a The sequence which was obtained using the 
FusionCatcher software with the fastq files of the RNA sequencing data. b Partial sequence chromatogram of the PCR amplified cDNA fragment 
showing the fusion (arrow) of IKZF1 and TYW1. c Ideogram of chromosome 7 showing the mapping position of IKZF1 (vertical red line) and TYW1 
(vertical green line). d Diagram showing the FISH probe (RP11-813K3 and RP11-95E2) for IKZF1. Additional genes in this region are also shown. e 
Diagram showing the FISH probe (RP11-458F8 and RP11-166O4) for TYW1. Additional genes in this region are also shown. f FISH on interphase 
nuclei with the IKZF1 (red signal) and TYW1 (green signal) probes showing a red signal, a green signal, and two yellow-fusion signals (arrow)
Page 7 of 8Panagopoulos et al. Exp Hematol Oncol            (2019) 8:12 
leukemia [20]. The deletion of 30  Mb in 5q32q35.3, 
found by aCGH and FISH using a PDGFRB breakapart 
probe, started within PDGFRB (5q32), indicating the 
presence of a PDGFRB-fusion gene which we set out to 
find using RNA sequencing. Combining RNA sequenc-
ing, PCR/Sanger sequencing, and FISH methodologies 
we found and verified two fusion transcripts: The first 
was a novel in-frame GTF2I–PDGFRB fusion tran-
script. Due to the extensive homology of the GTF2I 
gene with two pseudogenes, GTF2IP1 and GTF2IP4, 
neither RNA sequencing nor the subsequent PCR/
Sanger sequencing analyses could verify the precise 
fusion. FISH analyses based on hybridization with spe-
cific probes for the GTF2I and PDGFRB genes helped 
to identify the fusion as a GTF2I–PDGFRB, how-
ever. Similar to the FISH experiments with the PDG-
FRB breakapart probe, the fusion signal suggesting a 
GTF2I–PDGFRB hybrid gene was seen on interphase 
nuclei but not on the examined metaphase spreads. In 
all likelihood, the leukemic cells did not divide in vitro.
Based on the reference sequences NM_032999.3/
NP_127492.1 (GTF2I) and NM_002609.3/NP_002600.1 
(PDGFRB), the GTF2I–PDGFRB fusion gene would 
code for a putative 1671 amino-acid-residues (aa) 
chimeric protein containing almost the entire GTF2I 
protein (979 out of 998 aa) and the part of PDGFRB 
(aa 415 to 1106 in NP_002600.1) which contains the 
catalytic domain of the protein tyrosine kinase. The 
putative GTF2I–PDGFRB fusion protein seems to be 
an abnormal protein tyrosine kinase in a similar way 
to what has been seen with other PDGFRB fusion pro-
teins [21].
Hematologic neoplasms with PDGFRB-fusion genes 
can be treated with tyrosine kinase inhibitors [22–24]. 
Whether this applies also to the present case, remains 
unknown since complete remission was obtained using 
standard high-risk ALL treatment.
The second novel fusion transcript was an out-of-
frame IKZF1–TYW1 which would code for a trun-
cated 159 aa IKZF1 protein containing the first 140 
aa of IKZF1 (NP_006051) and 19 aa resulting from 
the fusion with TYW1. The IKZF1 and TYW1 genes 
were mapped on chromosome subbands 7p12.2 and 
7q11.21. Thus, IKZF1–TYW1 was most probably the 
product of a 7p12.2/7q11.21 recombination event: 
maybe an inv(7)(p12q11) or a t(7;7)(p12;q11) rear-
rangement. Fusions of IKZF1 with various partner 
genes have been reported before in ALL [25, 26]. How-
ever, to the best of our knowledge, this is the first time 
that an IKZF1–TYW1 fusion transcript is reported. 
Alterations of IKZF1 (often deletions) are known to be 
strongly associated with BCR-ABL1-positive and Ph-
like ALL [15, 16].
Conclusions
The examined pediatric leukemia was a Ph-like ALL 
which carried a novel GTF2I–PDGFRB fusion gene, a 
novel IKZF1–TYW1 fusion gene, and submicroscopic 
deletions on chromosome bands 5q32q35.3, 7q34 
(within TCRB), 9p13 (PAX5), 10q26.13 (DMBT1), and 
14q32.33 (within the IGH locus).
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